The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer
NCT ID: NCT02523495
Last Updated: 2018-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2012-06-30
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
NCT05414461
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149
A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients
NCT04716257
A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases
NCT06903325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Build a biological specimen banks of metastasis colorectal cancer through collecting blood samples from those patients who have reached an agreement with us.
3. Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer.
4. To extract DNA from the blood and explore some biomarkers that related to target therapy in metastasis colorectal cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Receive target therapy over half a year
3. Have a measurable lesions
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xianglin Yuan
Professor, Chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yuan Xianglin, Professional
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJCC003-TTMCRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.